Bayer (ETR:BAYN) Rating Reaffirmed
In recent note revealed to investors and clients on 8 December, The “Hold” rating of Bayer (ETR:BAYN) shares was reiterated by Jefferies & Company Inc., who now has a EUR 125.00 target price per share on the stock. Jefferies & Company Inc.’s target price per share gives a possible upside of 5.89% from the last stock price of the company.
From a total of 18 analysts covering Bayer (ETR:BAYN) stock, 9 rate it a ”Buy”, 0 a “Sell”, and 9 a ”Hold”. This means that 50% of the ratings are positive. The highest target price is €160 while the lowest target price is €121. The mean of all analyst targets is €142.44 with a 20.20% above today’s (€118.5) stock price. Bayer was the topic of 51 analyst reports since July 22, 2015 according to the firm StockzIntelligence Inc. Bankhaus Lampe upgraded shares on December 3 to “Buy” rating. Commerzbank maintained shares with “Hold” rating and €121 target share price in a report from a November 7. DZ-Bank AG upgraded BAYN stock in a recent report from November 20 to “Buy” rating. Landesbank maintained the rating on October 31. Landesbank has a “Hold” rating and a €125 price target on shares. Finally, Bernstein upgraded the stock to “Outperform” rating in a report issued on a November 13.
The stock increased 1.76% or EUR 2.05 on December 7, striking EUR 118.5. Approximately 1.83 million shares of stock traded hands or 3.98% up from the average. Bayer AG (ETR:BAYN) has 0.00% since May 11, 2015 and is . It has outperformed by 1.08% the S&P500.
Bayer AG is a strategic management holding company. The company has a market cap of 97.99 billion EUR. The Company’s business are organized into three subgroups: Bayer HealthCare, Bayer CropScience and Bayer MaterialScience, supported by the service companies Bayer Business Services, Bayer Technology Services and Currenta. It has 26.9 P/E ratio. Bayer HealthCare researches, develops, makes and markets products to improve the health of people and animals.